14-3-3∈ and 14-3-3σ Inhibit Toll-like Receptor (TLR)-mediated Proinflammatory Cytokine Induction (Retracted Article)
14-3-3∈ and 14-3-3σ Inhibit Toll-like Receptor (TLR)-mediated Proinflammatory Cytokine Induction (Retracted Article)
复制标题
DOI:
10.1074/jbc.m112.367490
复制
发表时间:
2012-11-09
影响因子:
4.8
通讯作者:
Miggin, Sinead M.
中科院分区:
文献类型:
--
作者:
Butt, Aisha Qasim;Ahmed, Suaad;Miggin, Sinead M.
Toll-like receptors (TLRs) are a group of pattern recognition receptors that play a crucial role in the induction of the innate immune response against bacterial and viral infections. TLR3 has emerged as a key sensor of viral double-stranded RNA. Thus, a clearer understanding of the biological processes that modulate TLR3 signaling is essential. Limited studies have applied proteomics toward understanding the dynamics of TLR signaling. Herein, a proteomics approach identified 14-3-3 is an element of and 14-3-3 sigma proteins as new members of the TLR signaling complex. Toward the functional characterization of 14-3-3 is an element of and 14-3-3 sigma in TLR signaling, we have shown that both of these proteins impair TLR2, TLR3, TLR4, TLR7/8, and TLR9 ligand-induced IL-6, TNF alpha, and IFN-beta production. We also show that 14-3-3 is an element of and 14-3-3 sigma impair TLR2-, TLR3-, TLR4-, TLR7/8-, and TLR9-mediated NF-kappa B and IFN-beta reporter gene activity. Interestingly, although the 14-3-3 proteins inhibit poly(I: C)mediated RANTES production, 14-3-3 proteins augment Pam(3)CSK(4), LPS, R848, and CpG-mediated production of RANTES (regulated on activation normal T cell expressed and secreted) in a Mal (MyD88 adaptor-like)/MyD88-dependent manner. 14-3-3 is an element of and 14-3-3 sigma also bind to the TLR adaptors and to both TRAF3 and TRAF6. Our study conclusively shows that 14-3-3 is an element of and 14-3-3 sigma play a major regulatory role in balancing the host inflammatory response to viral and bacterial infections through modulation of the TLR signaling pathway. Thus, manipulation of 14-3-3 proteins may represent novel therapeutic targets for inflammatory conditions and infections.